• Surgical Oncology Insight Banner Ad x

ADVERTISEMENT

Global Header
MENU

Annals of Surgical Oncology

Article Search
Publish and Submit
Landmark Series
ASO Research Letters Ongoing Clinical Research
Speaking of SurgOnc®

HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY

Weekly Update

Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

2024-10-03-A

October 3, 2024

Citation: Feng, J., Wang, L., Yang, X. et al. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 31, 272–283 (2024). https://doi.org/10.1245/s10434-023-14430-2

Synopsis:  The present study explores the clinical utility and response of pretreatment  pan-immune-inflammation value (PIV) to neoadjuvant immunochemotherapy (NICT) in esophageal squamous cell carcinoma (ESCC). Owing to better prognostic stratification, pretreatment PIV was found to be a novel, sensitive, and effective indicator in ESCC receiving NICT. The prognostic results of PIV need to be further verified in more and more prospective studies.

Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study

October 3, 2024

Citation: Doppenberg, D., Stoop, T.F., van Dieren, S. et al. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. Ann Surg Oncol 31, 1919–1932 (2024). https://doi.org/10.1245/s10434-023-14680-0

Synopsis: Elevated serum CEA at baseline is associated with impaired overall survival (OS) and may be a useful tool, both for decision-making at staging and at time of response evaluation. Although serum CEA dynamics are not predictive for OS, serum CEA normalization seems to be a potentially valuable parameter but has to be investigated in larger studies.

2024-10-03-B
Visit the Annals of Surgical Oncology Featured Articles Archive

Listen to the ASO's podcast, Speaking of SurgOnc®

Speaking of SurgOnc Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).

The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who expands upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.

Listen to the podcast here.

ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.

Join the conversation! Follow the journal on Twitter and Instagram. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.

twitter icon instagram icon

Society of Surgical Oncology

9525 West Bryn Mawr Avenue, Suite 870
Rosemont, IL 60018 / Phone: 847-427-1400

© Society of Surgical Oncology. 2010-2024.

Scroll to Top
X-twitter Linkedin Facebook-f Youtube